Published in final edited form as:

J Med Chem. 2012 March 8; 55(5): 2242–2250. doi:10.1021/jm201506e.

Design, Synthesis and Biological Evaluation of 1-[(2-benzyloxyl/alkoxyl) methyl]-5-halo-6-arylluracils as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Improved Drug Resistance Profile

Xiaowei Wang^{a,#}, Jianfang Zhang^{d,#}, Yang Huang^{c,#}, Ruiping Wang^d, Liang Zhang^a, Kang Qiao^a, Li Li^a, Chang Liu^d, Yabo Ouyang^c, Weisi Xu^c, Zhili Zhang^a, Liangren Zhang^b, Yiming Shao^c, Shibo Jiang^e, Liying Ma^{c,*}, and Junyi Liu^{a,b,*}

^aDepartment of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing 100191

^bState Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191

^cState Key Laboratory for Infection Disease Prevention and Control, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention, Beijing 102206

^dCollege of Pharmaceutical Sciences, Capital Medical University, Beijing 100069

^eMOE/MOH Key Laboratory of Medical Molecular Virology, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai 200032, China

Abstract

Since the emergence of drug-resistant mutants has limited the efficacy of non-nucleoside reverse transcriptase inhibitors (NNRTIs), it is essential to develop new antivirals with better drug-resistance and pharmacokinetic profiles. Here we designed and synthesized a series of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-arylluracils, the HEPT analogues, and evaluated their biological activity using Nevirapine and **18** (TNK-651) as reference compounds. Most of these compounds, especially **6b**, **7b**, **9b**, **11b** and **7c**, exhibited highly potent anti-HIV-1 activity against both wild-type and NNRTI-resistant HIV-1 strains. The compound **7b**, that had the highest selectivity index (SI = 38,215), is more potent than Nevirapine and **18**. These results suggest that introduction of halogen at the C-5 position may contribute to the effectiveness of these compounds against RTI-resistant variants. In addition, *m*-substituents on the C-6 aromatic moiety could significantly enhance activity against NNRTI-resistant HIV-1 strains. These compounds can be further developed as next-generation NNRTIs with improved antiviral efficacy and drug-resistance profile.

Keywords

HIV-1; Non-nucleoside reverse transcriptase inhibitors (NNRTIs); Drug-resistance

*To whom correspondence should be addressed. Phone/Fax: +86-10-82805203, jyliu@bjmu.edu.cn (JL); or Phone: +86-10-58900976, Fax: +86-10-58900980, mal@chinaaids.cn (LM).

#These authors have equal contribution

Introduction

The reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) is an attractive target for development of drugs used in the treatment of HIV-1 infection and AIDS. It is a multifunctional enzyme critical in viral replication. Currently, two functionally distinct classes of HIV-1 RT inhibitors (nucleoside and non-nucleoside) have been discovered and are being used clinically. Especially, non-nucleoside RT inhibitors (NNRTIs), with a wide range of chemically diverse structures, have gained a definitive and important place in clinical use based on their unique antiviral potency with generally low toxicity and favorable pharmacokinetic properties.^{1–3} To date, four NNRTIs have been approved for clinical use: Nevirapine, Delavirdine, Efavirenz and Etravirine.^{4–9}

Crystal structures of several RT/NNRTI complexes clearly show that NNRTIs bind to a hydrophobic pocket (the non-nucleoside inhibitor binding pocket, NNIBP) in the p66 palm subdomain near the polymerase active site. Upon binding, NNRTIs cause a distortion of the catalytic aspartate site.^{10–12} Like other types of anti-HIV drugs, the therapeutic efficacy of NNRTIs has been limited by the emergence of mutants that show cross-resistance to other structurally unrelated drugs.^{13–17} Therefore, it is essential to develop new NNRTIs with improved pharmacokinetic and drug-resistance profiles.

Among more than 50 different series of NNRTIs that have been reported so far, 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio)thymine (HEPT) was the first compound shown to target specifically the HIV-1 RT.¹⁸ Here we designed and synthesized 22 HEPT (**16**) derivatives, and detected their inhibitory activity on HIV-1 RT activity. Then, we selected 11 active compounds for testing their antiviral activities against HIV-1_{SF33}, a laboratory-adapted HIV-1 X4/R5 dual tropic strain, and HIV-1_{A17}, an NNRTI-resistant variant. Based on the results, we will delineate their structural features and gain insight into how the major chemical substitutions on the pyrimidine backbone affect the activity of these inhibitors against NNRTI-resistant HIV-1 strains.

Molecular Design

Structure and activity relationship studies have developed such promising **16** analogues as **17** (MKC-442) and **18** (TNK-651)^{19–21} (Figure 1), and the substituent of C-5 and C-6 on the pyrimidine ring have been revealed as very important for antiviral activity.^{22–23} Interestingly, **17** and **18**, with their bulky isopropyl groups at C-5 position, have been shown to counteract the Tyr181 residue,²⁴ thus forcing it into a position where strong interaction with the 6-benzyl group of the inhibitor can take place. In contrast, the C-5 methyl group in **16** does not produce any “trigger effect”, but only brings a slight perturbation of the Tyr181 side-chain conformation.

Although considerable research has been expended in understanding the structure and activity relationship of **16** analogues, little information can be found to explain the effect of varying both electronic effect and steric hindrance of the **16** series at the C-5 position with halogen. Compared to **18**, for example, the C-5 halogen atom has a large electron cloud density, which could form an interaction with the binding site of RT and play an important role in improving anti-HIV-1 activity. Moreover, the large atomic radius of C-5 halogen may also provide a steric hindrance role, when compared with C-5 isopropyl of **18**, and could trigger the conformation of a C-6 aromatic ring. In addition, modification on the C-6 by introduction of *m*-dimethyl chains or difluoro moiety onto the phenyl ring may result in closer interactions with non-nucleoside binding pocket (NNBP) than can be achieved with **18**.

To investigate the role of hydrogen bonds, we designed and synthesized a series of compounds by exchanging C-4 -OH for -NH₂, expecting that two hydrogen bonds could be formed between the N₃/C₄ positions with the carbonyl group of Lys101. Computational studies on the possible binding mode of these **16** derivatives in the NNBP of HIV-1 RT suggest that the introduction of a further anchor, which acts as both donor and acceptor of hydrogen bonds, would potentially lead to more activity against HIV-1 viruses.²⁵

To verify the structure and activity relationship of our design, target compounds 1-[(2-benzyloxy)methyl]-5-iodo-6-aryluracils (**7a**, **7b** and **7c**) were flexibly docked into the binding site of HIV-1 RT (PDB entry 1RT2, complexes with **18**), using the GOLD3.0.1 docking program. It was revealed that the binding mode of **7a**, **7b** and **7c** has approximate conformations comparable to that of the RT/**18** complex (Figure 2).

Based on the above results, we then synthesized a series of novel uracil derivatives (Figure 1), which are characterized by methyl and fluorine at the *meta* positions of the phenyl ring, and all possess a halo or dimethylamino moiety at position 5 of the pyrimidine. Title compounds were tested for their activities against HIV-1 in both cell-based assay and reverse transcriptase (RT) assay in comparison with **18** and Nevirapine, which were used as reference drugs. The results were described below.

Chemistry

A conventional strategy of synthesizing the newly designed compounds is described in Scheme 1. We prepared the 3-oxo esters **1a–c** according to the method of Hannick and Kishi²⁶ by reaction of 2-bromoacetate with phenylacetonitrile or 3,5-dimethylphenylacetonitrile or 3,5-difluorophenyl acetonitrile, respectively. The β -ketoesters (**1**) was thus formed and were then converted by reaction with thiourea and sodium in ethanol into 2-thiouracil (**2**),²⁷ which were refluxed with 10% chloroacetic acid to yield 6-(arylmethyl)uracils (**3**).²⁸ Halogenations at C-5 position of **3** by reaction of PbO₂ with halogen in glacial acetic acid at room temperature led to **4a–5b** in high yield. Compounds **4a–5b** were silylated in situ with *N,O*-bis(trimethylsilyl)acetamide (BSA) and then N-1 alkylated with the appropriate alkyl chloromethyl ether, in the presence of LiI, to give **6a–9b**^{29, 30} in good yield, followed by reaction with dimethylamino aqueous solution to get **10a–11b**.^{31, 32} Finally, the uracil moiety was successfully converted to the 4-(1,2,4-triazolyl) pyrimidinone derivatives. Without purification, subsequent ammonia treatment yielded the target compounds **12a–15b**.^{33–35} Structure assignments of these compounds were identified by NMR and mass spectral data.

Results and Discussion

Docking studies of the title compounds into the HIV-1 NNBP revealed that they could bind to the NNBP and displayed a slightly different binding mode compared to HIV-1 RT/**18** complex. In particular, the C-5-iso-propyl group of **18**, which is responsible for the “trigger action”, does not coincide with halogen on C-5 position of compounds **6a–9b**. Moreover, the disubstituents to the phenyl rings lie in different positions (Figure 2).

Within the NNBP, target compounds establish several ligand-receptor interactions. Inspection of the **7a**/RT complex (Figure 3) may be characterized as follows: (i) A hydrogen bond donated by the 3-NH function of the pyrimidine to the carbonyl oxygen of Lys101 is a crucial factor for anti-HIV-1 activity. (ii) Unusual interactions between the iodine atom and an electronegative atom, such as the Tyr188 carbonyl oxygen, were observed in the **7a**/RT structure. Here, demonstrating electrostatic dynamics, the iodine atom serves as an electron acceptor for the Tyr188 carbonyl oxygen (Figure 3). The results suggested that halogen, especially iodine on the pyrimidine ring, has anisotropic surface charge distributions with

significant electropositive patches which could serve as Lewis acid. Thus, the introduction of electron-withdrawing substituents on the pyrimidine ring might increase the electrostatic interaction of the compound with the carbonyl oxygen of Tyr188 residue. In addition, the iodine atom of **7a** is only 3.35 Å away from the carbonyl oxygen of Tyr188, which is less than the van der Waals contact distance of 3.55 Å, and the angle C-X...O (X is a halogen) of **7a** is 157.93°, which is close to the predicted ideal angle of 165°. (iii) Favorable π -stacking interactions of the **7a** phenyl ring with a hydrophobic pocket, as defined by the side-chains of Tyr188, Trp229, Tyr181, Leu100 and Phe227, especially the Tyr188 and Tyr181 residues, were observed.

Interestingly, the antiviral results show that the chain at C-6 position with different substituents on the aromatic moiety, which is located in a hydrophobic region delimited by Tyr181, Tyr188, Phe227 and Trp229, significantly enhances the activity against HIV-1 and demonstrates improved resistance profiles. We have investigated **7b**, **9b** and **11b** by introduction of *m*-dimethyl substituents onto the phenyl ring intended to optimize interactions with Trp229, which is less mutable in immunodeficiency virus reverse transcriptase, by reducing the dependence on binding to Tyr181. Molecular modeling revealed that methyl groups attached to the 3' and 5' positions of the 6-benzyl group would be buried in a deep hydrophobic region near Trp229 and Phe227 (Figure 3).

The significant difference in behavior against the drug resistant mutants of **7b** is fully explained by the presence of the additional *m*-methyl groups, sitting comfortably in a deep hydrophobic region of the NNRTI binding site and, hence, increasing the van der Waals contacts and σ - π interactions to the conserved Trp229 and Phe227, as well as the other residues in this region. As a result, the compound derives a fraction of its binding energy from the interaction with the Tyr181 side chain.

Furthermore, the phenyl moiety at the terminus of N-1 side chain extends into a tunnel that leads out of the NNIBP toward the catalytic site comprised of Tyr318 and Pro236 (Figure 4). Particularly, Tyr318 could provide the π - π interaction with the phenyl ring of the N-1 group. We presume that the steric hindrance aroused by dimethyl of **7b** would change the conformation of the ligand binding model in NNIBP with the rotation of the terminal phenyl moiety at the N-1 side chain and result in significantly improving the inhibition of HIV-1 RT, suggesting that structure-based modifications at this location might enhance the activity.

Compared to **7b**, replacement of dimethyl by fluoro at the C-6 aromatic ring could also result in high potency against wild HIV-1 and Tyr181Cys mutant virus. This finding could be explained by a putative π -stacking interaction which would be improved between the electron-deficient benzene ring of the ligand and the electron-rich benzene ring of Tyr188, as introducing the 3,5-difluorophenylmethyl moiety on the C-6 aromatic ring. Moreover, the contact distance between the iodine atom of **7c** and the carbonyl oxygen of Tyr188 is 3.27 Å in van der Waals distance, and the halogen bonding angle ((C-X...O), 155.44°) is similar to the ideal angle 165°.

Upon replacing the C-4 -OH by -NH₂, the binding mode changed such that the distance between the iodine with the carbonyl oxygen of Try188 (4.85 Å) became longer than the van der Waals distance (3.55 Å). Furthermore, the π -stacking interaction, which usually lies in our target compounds, was not observed in compound **13a**.

The title compounds were tested for their inhibitory activity against HIV-1 RT using a poly(rA)/oligo(dT)15 homopolymer template and Nevirapine as a reference compound.³⁶ As shown in Table 1, nine compounds showed promising anti-RT activities. Particularly, compound **7b** is 1373- and 6.7-fold more potent than Nevirapine and **18**, respectively. However, the anti-RT activities of compounds **12a–15b** significantly decreased.

Subsequently, the anti-HIV-1 activity and cytotoxicity of **6a–11b** were determined, using Nevirapine and **18** as reference compounds. As shown in Table 2, all these compounds were capable of inhibiting infection by HIV-1_{SF33} in MT4 cells with EC₅₀ values at 2 nM – 2.071 μM. Among these compounds, **7b**, **11b**, **9b**, **6b** and **7c** were about 325- to 46-fold more potent than Nevirapine. They had higher antiviral activity and selectivity index (SI) than **18**. In addition, the above-mentioned compounds displayed much higher potency against HIV-1_{A17}, the NNRTI-resistant mutant strain with K103N and Y181C mutations, than Nevirapine and **18**.

Conclusion

In summary, we have designed a series of 1-[(benzyloxy/alkoxy)methyl]-5-halo-6-aryl uracil and 1-[(benzyloxy/alkoxy)methyl]-4-amino-5-halo-6-aryl uracil (**6a–15b**) as inhibitors of HIV-1 RT and described an efficient method of synthesis. Interestingly, compounds **7a–c**, **9a–b** and **11a–b** showed much more potent antiviral activities than Nevirapine, both in enzyme and cell-based assays. An excellent correlation was found between EC₅₀ values for inhibiting HIV-1 infection and IC₅₀ values for inhibiting HIV-1 RT activity, confirming that these compounds act as inhibitors of the HIV-1 RT.

Some of the dimethylsubstituent compounds (**6b**, **7b**, **9b** and **11b**) had comparable antiviral activity against wild-type HIV-1 to that of **18**. However, they were more effective than **18** against the NNRTI-resistant HIV-1 strain A17. These may result from the introduction of two methyl groups at the C-6 aromatic ring, which could increase contacts to the conserved Trp229 and modulate the terminal phenyl moiety at the N-1 side chain.

Meanwhile, the difluoro-substituted derivative (compound **7c**) showed a significant anti-HIV-1 potency on HIV-1_{SF33} and HIV-1_{A17} infection in MT4 cells, compared to that of Nevirapine and **18**. These results appear to confirm our hypothesis that a favorable effect of 3,5-difluorogenation related to an attractive π -stacking interaction takes place with the benzene rings of Tyr188. Also, it is consistent with the hypothesis that the presence of two electron-withdrawing groups at the *meta* position of the phenyl ring would enhance the beneficial electronic effect on the antiviral activity produced by 3,5-difluorogenation.

The SI values of the major **16** derivatives for inhibiting HIV-1_{SF33} infection are in the range of 39 to 38,000. Strikingly, the compound **7b**, which has the highest SI value, is highly effective against the NNRTI-resistant HIV-1 strain A17, suggesting a great potential to further develop it as a new anti-HIV-1 drug.

Experimental Section

Chemistry

The structural characterization was done by NMR and high resonance mass spectrometer (HRMS). The purity of tested compounds was determined by HPLC (DIONEX Ultimate 3000 HPLC system). All the assayed compounds displayed a purity $\geq 95\%$ (Table S1). Melting points were determined on a WBS-1B type digital melting-point apparatus and are uncorrected. NMR spectra were recorded on a Bruker Avance 300 or Avance 500 with tetramethylsilane (TMS) as an internal standard, and chemical shifts are reported in δ (ppm). All the reactions were routinely monitored by TLC, which was performed on aluminum-backed silica gel plates (60 F254) with spots visualized by UV light. Silica gel (0.040 – 0.064 mm) was used for column chromatography and analytical silica gel for TLC plates. Unless otherwise stated, all reagents were purchased from commercial sources. When necessary, they were purified and dried by standard methods. Organic solutions were dried over anhydrous sodium sulfate.

6-(arylmethyl)-1-alkyl-5-halouracils 6a–9b

General Procedure: Activated zinc dust (18 g, 275 mmol) was suspended in dry THF (125 mL) at reflux, and a few drops of ethyl 2-bromoacetate were added to initiate the reaction. After the appearance of a green color (ca. 45 min), arylacetonitrile (4.50 mmol) was added in one portion followed by dropwise addition of ethyl 2-bromoacetate (10 mmol) over a period of 1 h. The reaction mixture was refluxed for an additional 10 min, diluted with THF (3×125 mL), and quenched with aqueous K_2CO_3 (50%, 54 mL). Rapid stirring for 45 min gave two distinct layers. The upper layer was decanted, the residue was washed with THF (2×100 mL), and the combined THF fractions were treated with aqueous HCl (10%, 50 mL) at room temperature for 45 min. The mixture was concentrated *in vacuo*, diluted with CH_2Cl_2 (300 mL), and washed with saturated aqueous $NaHCO_3$ (200 mL) to pH 7. The organic phase was dried (Na_2SO_4) and evaporated *in vacuo* to give an oil, which was used without further purification for the synthesis of compound **2a–c**.

Sodium (2.2 g, 96 mmol) was dissolved in anhydrous EtOH (80 mL), and thiourea (5.2 g, 68 mmol) and compounds **1a–c** (4.5 mmol) were added to the clear solution. The reaction mixture was refluxed for 4 h and evaporated under reduced pressure until nearly dry, and the residue was redissolved in H_2O (50 mL). The 2-thiouracil was precipitated by acidification to pH 4 with 2N aq HCl.

The precipitated 2-thiouracil was desulfurized by suspension in 10% aqueous chloroacetic acid (100 mL) and subsequent reflux for 24 hours. After cooling to room temperature, the precipitate was filtered off, washed with cold EtOH and Et_2O , and finally dried *in vacuo* to give compounds **3a–c** as a white solid.

6-arylmethyluracil **3a–c** (0.5 mmol) was suspended in glacial HOAc (3 mL). $Pb(OAc)_2$ (0.22 mmol) was added in portions while stirring, followed by the addition of halogen (0.22 mmol). The suspension was stirred for 12 h at 50 °C and then diluted with H_2O (120 mL). The precipitate was isolated, washed with H_2O , and dried *in vacuo* to give **4a–c**, **5a–b** as a solid product.

6-(Arylmethyl)-5-halouracil **4a–c** and **5a–b** (0.42 mmol) were dissolved in dry $CHCl_3$ (10 mL), and *N,O*-Bis(trimethylsilyl) acetamide (BSA, 1.05 mmol) was added. After 30 min, the appropriate alkyl chloromethyl ether (0.51 mmol) and LiI (0.2 mmol) were added. The solution was stirred at room temperature for 4 h and then quenched with ice-cold sat. $NaHCO_3$ (25 mL). The aqueous phase was extracted with AcOEt (3×20 mL). The organic layer was dried with Na_2SO_4 and evaporated under reduced pressure. The residue was purified by silica column chromatography giving the product.

6-benzyl-1-ethoxymethyl-5-iodouracil (6a): white solid, yield 90%; mp 175–177 °C; 1H NMR (300 MHz, DMSO- d_6) δ 1.22 (t, 3H, $J = 6.9$ Hz, CH_2CH_3), 3.64 (q, 2H, $J = 6.9$ Hz, OCH_2CH_3), 4.58 (s, 2H, CH_2Ph), 5.24 (s, 2H, NCH_2O), 7.14–7.28 (m, 5H, aryl), 9.26 (s, 1H, NH); ^{13}C NMR (75 MHz, DMSO- d_6) δ : 15.01 (CH_2CH_3), 42.05 (CH_2Ph), 65.39 (OCH_2CH_3), 74.05 (NCH_2O), 79.17 (C-5), 127.48, 127.66, 129.38, 133.55 (aryl), 151.45 (C-6), 156.07 (C-2), 160.00 (C-4); m/z (ESI): HRMS (m/z) calcd for $C_{14}H_{15}IN_2O_3$ $[M + H]^+$ 387.02001, found 387.02021.

6-(3,5-dimethylbenzyl)-1-ethoxymethyl-5-iodouracil (6b): white solid, yield 89%; mp 177–178 °C; 1H NMR (300 MHz, DMSO- d_6) δ 1.23 (t, 3H, $J = 7.0$ Hz, CH_2CH_3), 2.32 (s, 6H, 2 CH_3), 3.65 (q, 2H, $J = 7.0$ Hz, OCH_2CH_3), 4.51 (s, 2H, CH_2Ar), 5.25 (s, 2H, NCH_2O), 6.79–6.96 (m, 3H, aryl), 9.29 (s, 1H, NH); ^{13}C NMR (75 MHz, DMSO- d_6) δ : 15.06 (CH_2CH_3), 21.35 (CH_3Ar -C6), 41.92 (CH_2Ph), 65.39 (OCH_2CH_3), 74.05 (NCH_2O), 79.07

(C-5), 127.13, 127.66, 133.30, 139.08 (aryl), 151.52(C-6), 156.33 (C-2), 160.13(C-4); m/z (ESI): HRMS (*m/z*) calcd for C₁₆H₁₉IN₂O₃ [M + H]⁺ 415.05131, found 415.05181.

6-(3,5-difluorobenzyl)-1-ethoxymethyl-5-iodouracil (6c): white solid, yield 70%; mp 198–200°C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.05 (t, 3H, J = 7.0 Hz, CH₂CH₃), 3.50 (q, 2H, J = 7.0 Hz, OCH₂CH₃), 3.97 (s, 2H, CH₂Ar), 5.19 (s, 2H, NCH₂O), 6.97–7.16 (m, 3H, aryl), 9.80 (s, 1H, NH); ¹³C NMR (100 MHz, DMSO-*d*₆) δ: 15.48 (CH₂CH₃), 41.82 (CH₂Ar), 65.17 (OCH₂CH₃), 71.26 (NCH₂O), 73.98 (C-5), 103.09, 112.32, 140.02, 164.15 (aryl), 151.39 (C-6), 153.39 (C-2), 161.29 (C-4); m/z (ESI): HRMS (*m/z*) calcd for C₁₄H₁₃F₂IN₂O₃ [M + H]⁺ 422.9939, found 423.00165.

6-benzyl-1-benzyloxymethyl-5-iodouracil (7a): white solid, yield 89%; mp 165–166°C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 4.57 (s, 2H, CH₂Ph), 4.67 (s, 2H, OCH₂Ph), 5.32 (s, 2H, NCH₂O), 7.12–7.41 (m, 10H, aryl), 8.90 (s, 1H, NH); ¹³C NMR (75 MHz, DMSO-*d*₆) δ: 42.10 (CH₂Ph-C6), 72.11 (OCH₂Ph), 74.01 (NCH₂O), 79.14 (C-5), 127.47 127.68, 127.84, 128.22, 128.56, 129.38, 133.46, 136.89 (aryl), 151.20 (C-6), 155.85 (C-2), 159.64 (C-4); m/z (ESI): HRMS (*m/z*) calcd for C₁₉H₁₇IN₂O₃ [M + H]⁺ 449.03566, found 449.03562.

1-benzyloxymethyl-6-(3,5-dimethylbenzyl)-5-iodouracil (7b): white solid, yield 85%; mp 166–167°C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 2.31(s, 6H, 2CH₃), 4.49 (s, 2H, CH₂Ar), 4.68 (s, 2H, OCH₂Ph), 5.33 (s, 2H, NCH₂O), 6.72–7.41 (m, 8H, aryl), 9.11 (s, 1H, NH); ¹³C NMR (75 MHz, DMSO-*d*₆) δ: 21.35(CH₃Ar-C6), 41.99 (CH₂Ar-C6), 72.07 (OCH₂Ph), 74.00 (NCH₂O), 79.14 (C-5), 125.11, 127.03, 127.68, 127.88, 128.23, 128.58, 129.36, 133.21, 136.97, 139.08 (aryl), 151.41(C-6), 156.11 (C-2), 159.93 (C-4); m/z (ESI): HRMS (*m/z*) calcd for C₂₁H₂₁IN₂O₃ [M + H]⁺ 477.06696, found 477.06701.

6-(3,5-difluorobenzyl)-1-benzyloxymethyl-5-iodouracil (7c): white solid, yield 58%; mp 175–177°C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 4.46 (s, 2H, CH₂Ar), 4.61 (s, 2H, OCH₂Ph), 5.24 (s, 2H, NCH₂O), 6.72–7.34 (m, 8H, aryl), 9.86 (s, 1H, NH); ¹³C NMR (100 MHz, DMSO-*d*₆) δ: 41.66 (CH₂Ar-C6), 72.09 (OCH₂Ph), 74.01 (NCH₂O), 79.99 (C-5), 103.31, 110.46, 127.97, 128.35, 128.60, 136.66, 137.35, 164.71 (aryl), 151.46 (C-6), 154.31 (C-2), 162.22 (C-4); HRMS (*m/z*): calcd for C₁₉H₁₅F₂IN₂O₃ [M + H]⁺ 485.0095, found 485.01706.

6-benzyl-5-bromo-1-ethoxymethyluracil (8a): white solid, yield 78%; mp 170–172°C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 1.21 (t, 3H, J = 6.9 Hz, CH₂CH₃), 3.62 (q, 2H, J = 6.9 Hz, OCH₂CH₃), 4.54 (s, 2H, CH₂Ph), 5.25 (s, 2H, NCH₂O), 7.21–7.96 (m, 5H, aryl), 9.36 (s, 1H, NH); ¹³C NMR (75 MHz, DMSO-*d*₆) δ: 15.03 (CH₂CH₃), 42.08 (CH₂Ph), 65.37 (OCH₂CH₃), 74.02 (NCH₂O), 101.9 (C-5), 127.47, 127.64, 129.39, 133.50 (aryl), 151.43(C-6), 156.10 (C-2), 160.05 (C-4); HRMS (*m/z*): calcd for C₁₄H₁₅BrN₂O₃ [M + H]⁺ 339.03388, found 339.03409.

6-(3,5-dimethylbenzyl)-5-bromo-1-ethoxymethyluracil (8b): white solid, yield 82%; mp 192–193°C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.24 (t, 3H, J = 7.0 Hz, CH₂CH₃), 2.32 (s, 6H, 2CH₃), 3.66 (q, 2H, J = 7.0 Hz, OCH₂CH₃), 4.41 (s, 2H, CH₂Ar), 5.23 (s, 2H, NCH₂O), 6.79–6.95 (m, 3H, aryl), 9.30 (s, 1H, NH); ¹³C NMR (125MHz, DMSO-*d*₆) δ: 15.05 (CH₂CH₃), 21.33(CH₃Ar-C6), 37.33(CH₂Ar-C6), 65.40 (OCH₂CH₃), 73.74 (NCH₂O), 101.83(C-5), 125.21, 129.33, 133.35, 139.08 (aryl), 151.07(C-6), 153.44 (C-2), 158.91(C-4); HRMS (*m/z*): calcd for C₁₆H₁₉BrN₂O₃ [M + H]⁺ 367.06518, found 367.06542

6-benzyl-1-benzyloxymethyl-5-bromouracil (9a): white solid, yield 80%; mp 168–170°C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 4.47 (s, 2H, CH₂Ph), 4.68 (s, 2H, OCH₂Ph), 5.56 (s, 2H, NCH₂O), 7.27–7.40 (m, 10H, aryl), 9.07 (s, 1H, NH); ¹³C NMR (75 MHz, DMSO-

d6) δ : 37.51 (CH₂Ph-C6), 72.11 (OCH₂Ph), 73.71 (NCH₂O), 101.97 (C-5), 127.54, 127.67, 127.85, 128.22, 128.56, 129.35, 133.54, 136.88 (aryl), 150.86 (C-6), 152.92 (C-2), 158.50 (C-4); HRMS (*m/z*): calcd for C₁₉H₁₇BrN₂O₃ [M + H]⁺ 401.04953, found 401.05027.

6-(3,5-dimethylbenzyl)-1-benzyloxymethyl-5-bromouracil (9b): white solid, yield 78%; mp 157–159°C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.30 (s, 6H, 2CH₃), 4.39 (s, 2H, CH₂Ar), 4.69 (s, 2H, OCH₂Ph), 5.31 (s, 2H, NCH₂O), 6.72–7.41 (m, 8H, aryl), 9.39 (s, 1H, NH); ¹³C NMR (125 MHz, DMSO-*d*₆) δ : 21.32 (CH₃Ar-C6), 37.37 (CH₂Ar-C6), 72.07 (OCH₂Ph), 73.68 (NCH₂O), 101.92 (C-5), 125.19, 127.77, 127.82, 127.90, 128.46, 128.58, 129.36, 133.28, 136.94, 139.07 (aryl), 151.04 (C-6), 153.20 (C-2), 158.83 (C-4); HRMS (*m/z*): calcd for C₂₁H₂₁BrN₂O₃ [M + H]⁺ 429.08083, found 429.08150.

6-(arylmethyl)-1-alkyl-5-dimethylaminouracils 10a–b, 11a–b

General Procedure: A mixture of 1-alkyl-6-(arylmethyl)-5-iodouracil (0.2 mmol), 33% NH(CH₃)₂ aqueous solution (2.4 mL) and 1,4-dioxane (2.4 mL) was reacted in high-pressure reactor at 80 °C for 1h. After cooling to room temperature, the reaction mixture was extracted with CH₂Cl₂ (2 × 25 mL). The combined organic layer was dried with Na₂SO₄ and evaporated under reduced pressure. The residue was purified by silica column chromatography giving the products.

6-benzyl-5-dimethylamino-1-ethoxymethyluracil (10a): white solid, yield 58%; mp 80–81°C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.21 (t, 3H, J = 7.0 Hz, CH₂CH₃), 2.73 (s, 6H, N(CH₃)₂), 3.62 (q, 2H, J = 7.0 Hz, OCH₂CH₃), 4.43 (s, 2H, CH₂Ph), 5.10 (s, 2H, NCH₂O), 7.14–7.36 (m, 5H, aryl), 9.44 (s, 1H, NH); ¹³C NMR (125 MHz, DMSO-*d*₆) δ : 15.06 (CH₂CH₃), 32.28 (CH₂Ph-C6), 43.64 (N(CH₃)₂), 65.02 (OCH₂CH₃), 73.17 (NCH₂O), 126.75 (C-5), 126.88, 127.47, 136.18, 138.66 (aryl), 151.68 (C-6), 152.85 (C-2), 161.42 (C-4); HRMS (*m/z*): calcd for C₁₆H₂₁N₃O₃ [M + H]⁺ 304.16557, found 304.16521.

6-(3,5-dimethylbenzyl)-5-dimethylamino-1-ethoxymethyluracil (10b): white solid, yield 50%; mp 171–173°C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.22 (t, 3H, J = 7.1 Hz, CH₂CH₃), 2.31 (s, 6H, CH₃Ph), 2.75 (s, 6H, N(CH₃)₂), 3.42 (q, 2H, J = 7.1 Hz, OCH₂CH₃), 4.36 (s, 2H, CH₂Ar), 5.11 (s, 2H, NCH₂O), 6.73–6.90 (m, 3H, aryl), 8.96 (s, 1H, NH); ¹³C NMR (125 MHz, DMSO-*d*₆) δ : 15.06 (CH₂CH₃), 21.29 (CH₃Ar-C6), 32.11 (CH₂Ar-C6), 43.66 (N(CH₃)₂), 65.02 (OCH₂CH₃), 73.17 (NCH₂O), 126.52 (C-5), 125.21, 128.52, 136.18, 138.66 (aryl), 151.47 (C-6), 153.16 (C-2), 161.11 (C-4); HRMS (*m/z*): calcd for C₁₈H₂₅N₃O₃ [M + H]⁺ 332.19687, found 332.19622.

6-benzyl-1-benzyloxymethyl-5-dimethylaminouracil (11a): white solid, yield 56%; mp 91–92°C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.72 (s, 6H, N(CH₃)₂), 4.43 (s, 2H, CH₂Ph), 4.67 (s, 2H, OCH₂Ph), 5.21 (s, 2H, NCH₂O), 7.25–7.39 (m, 10H, aryl), 9.17 (s, 1H, NH); ¹³C NMR (125 MHz, DMSO-*d*₆) δ : 32.27 (CH₂Ph-C6), 43.64 (N(CH₃)₂), 71.94 (OCH₂Ph), 73.29 (NCH₂O), 126.76 (C-5), 126.92, 127.47, 127.77, 128.03, 128.35, 128.52, 129.10, 136.34, 137.39 (aryl), 151.68 (C-6), 152.64 (C-2), 161.12 (C-4); HRMS (*m/z*): calcd for C₂₁H₂₃N₃O₃ [M + H]⁺ 366.18122, found 366.18047.

6-(3,5-dimethylbenzyl)-1-benzyloxymethyl-5-dimethylaminouracil (11b): white solid, yield 51%; mp 152–153°C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 2.28 (s, 6H, CH₃Ph), 2.72 (s, 6H, N(CH₃)₂), 4.34 (s, 2H, CH₂Ar), 4.67 (s, 2H, OCH₂Ph), 5.20 (s, 2H, NCH₂O), 6.70–7.39 (m, 8H, aryl), 9.10 (s, 1H, NH); ¹³C NMR (75 MHz, DMSO-*d*₆) δ : 21.29 (CH₃Ar), 32.07 (CH₂Ar-C6), 43.62 (N(CH₃)₂), 71.90 (OCH₂Ph), 73.31 (NCH₂O), 126.61 (C-5), 125.19, 127.47, 128.00, 128.35, 128.49, 136.07, 137.44, 138.65 (aryl), 151.68 (C-6), 152.64 (C-2), 161.12 (C-4); HRMS (*m/z*): calcd for C₂₃H₂₇N₃O₃ [M + H]⁺ 394.21252, found 394.21203.

4-amino-6-(arylmethyl)-1-alkyl-5-halouracils 12a–b, 13a–b, 14a–b, 15a–b

General Procedure: 1-alkyl-6-arylmethyl-5-halouracil (0.067 mmol) was added to the solution of 1,2,4-triazole (1.34mmol) and POCl₃ (0.53mmol) in the presence of triethylamine. After stirring for about 30 min., the solution became dark-red. Concentrated ammonia 1mL (25%~28%) was added dropwise to the mixture and reacted for another 1h. Extracted with dichloromethane, the combined organic layer was dried with Na₂SO₄ and evaporated *in vacuo*. The residue was purified by silica column chromatography to yield the products.

4-amino-6-benzyl-1-ethoxymethyl-5-iodouracil (12a): white solid, yield 46%; mp 150–152°C; ¹H NMR (300 MHz, DMSO-d₆) δ 1.12 (t, 3H, J = 6.9 Hz, CH₂CH₃), 3.46 (q, 2H, J = 6.9 Hz, OCH₂CH₃), 4.38 (s, 2H, CH₂Ph), 5.17 (s, 2H, NCH₂O), 7.12–7.37 (m, 5H, Ph), 8.23 (br, 2H, NH₂-C4); ¹³C NMR (75 MHz, DMSO-d₆) δ: 15.33 (CH₂CH₃), 41.98 (CH₂Ph), 64.26 (OCH₂CH₃), 67.60 (NCH₂O), 74.21 (C-5), 127.32, 127.83, 129.41, 133.22 (aryl), 151.16 (C-6), 156.89 (C-2), 164.75 (C-4); m/z (ESI): 386.2 (M+H)⁺

4-amino-6-(3,5-dimethylbenzyl)-1-ethoxymethyl-5-iodouracil (12b): white solid, yield 78%; mp 113–115°C; ¹H NMR (300 MHz, DMSO-d₆) δ 1.04 (t, 3H, J = 7.0 Hz, CH₂CH₃), 2.24 (s, 6H, 2CH₃), 3.49 (q, 2H, J = 7.0 Hz, OCH₂CH₃), 4.31 (s, 2H, CH₂Ar), 5.17 (s, 2H, NCH₂O), 6.73–6.89 (m, 3H, aryl), 8.49 (br, 2H, NH₂-C4); ¹³C NMR (75 MHz, DMSO-d₆) δ: 15.32 (OCH₂CH₃), 21.37 (CH₃Ar-C6), 41.66 (CH₂Ar-C6), 64.33 (OCH₂CH₃), 67.55 (NCH₂O), 74.26 (C-5), 125.44, 128.86, 135.01, 138.48 (aryl), 156.28 (C-6), 157.05(C-2), 164.75 (C-4); m/z (ESI): 414.3 (M+H)⁺.

4-amino-6-benzyl-1-benzyloxymethyl-5-iodouracil (13a): white solid, yield 58%; mp 138–139°C; ¹H NMR (500 MHz, DMSO-d₆) δ 4.39 (s, 2H, CH₂Ph), 4.55 (s, 2H, OCH₂Ph), 5.25 (s, 2H, NCH₂O), 7.09–7.34 (m, 10H, aryl), 7.98 (br, 2H, NH₂-C4); ¹³C NMR (125MHz, DMSO-d₆) δ: 41.85 (CH₂Ph-C6), 67.61 (OCH₂Ph), 70.80 (NCH₂O), 74.41 (C-5), 127.35, 127.87, 128.06, 128.13, 128.70, 129.43, 135.13, 138.12 (aryl), 156.14 (C-6), 156.85 (C-2), 164.80 (C-4); m/z (ESI): 448.3 (M+H)⁺.

4-amino-1-benzyloxymethyl-6-(3,5-dimethylbenzyl)-5-iodouracil (13b): white solid, yield 58%; mp 129–130°C; ¹H NMR (500 MHz, DMSO-d₆) δ 2.21(s, 6H, 2CH₃), 4.29 (s, 2H, CH₂Ar), 4.55 (s, 2H, OCH₂Ph), 5.23 (s, 2H, NCH₂O), 6.70–7.36 (m, 8H, aryl), 8.60 (br, 2H, NH₂-C4); ¹³C NMR (125MHz, DMSO-d₆) δ: 21.37(CH₃Ar-C6), 41.89 (CH₂Ar-C6), 68.06 (OCH₂Ph), 72.30 (NCH₂O), 78.04 (C-5), 126.11, 127.30, 127.86, 128.08, 128.32, 128.68, 129.40, 133.27, 136.97, 139.18 (aryl), 152.41(C-6), 155.01 (C-2), 160.03 (C-4); m/z (ESI): 476.4 (M+H)⁺.

4-amino-6-benzyl-5-bromo-1-ethoxymethyluracil (14a): white solid, yield 48%; mp decomposed >200°C; ¹H NMR (500 MHz, DMSO-d₆) δ 1.05 (t, 3H, J = 6.9 Hz, CH₂CH₃), 3.58 (q, 2H, J = 6.9 Hz, OCH₂CH₃), 4.46 (s, 2H, CH₂Ph), 5.23 (s, 2H, NCH₂O), 7.151–7.87 (m, 5H, aryl), 8.30 (br, 2H, NH₂-C4); ¹³C NMR (125 MHz, DMSO-d₆) δ: 15.07(CH₂CH₃), 41.96 (CH₂Ph), 64.73 (OCH₂CH₃), 74.01 (NCH₂O), 90.89 (C-5), 125.67, 128.14, 133.39, 139.50 (aryl), 152.43(C-6), 157.01 (C-2), 159.05 (C-4); m/z (ESI): 338.3, 340.2 (M+H)⁺.

4-amino-6-(3,5-dimethylbenzyl)-5-bromo-1-ethoxymethyluracil (14b): white solid, yield 91%; mp 111–112°C; ¹H NMR (500 MHz, DMSO-d₆) δ 1.04 (t, 3H, J = 7.0 Hz, CH₂CH₃), 2.24 (s, 6H, 2CH₃Ph), 3.50 (q, 2H, J = 7.0 Hz, OCH₂CH₃), 4.22 (s, 2H, CH₂Ar), 5.15 (s, 2H, NCH₂O), 6.74–6.89 (m, 3H, aryl), 8.40 (br, 2H, NH₂-C4); ¹³C NMR (125MHz, DMSO-d₆) δ: 15.31 (OCH₂CH₃), 21.35 (CH₃Ar-C6), 37.22 (CH₂Ar-C6), 64.32

(OCH₂CH₃), 74.08 (NCH₂O), 91.68 (C-5), 125.48, 128.89, 134.99, 138.48 (aryl), 154.14 (C-6), 155.67 (C-2), 162.66 (C-4); m/z (ESI): 366.3 (M+H)⁺.

4-amino-6-benzyl-1-benzyloxymethyl-5-bromouracil (15a): yield 60%; mp 148–149°C; ¹H NMR (500 MHz, DMSO-d₆) δ 4.30 (s, 2H, CH₂Ph), 4.55 (s, 2H, OCH₂Ph), 5.24 (s, 2H, NCH₂O), 7.11–7.34 (m, 10H, aryl), 8.00 (br, 2H, NH₂-C4); ¹³C NMR (125 MHz, DMSO-d₆) δ: 37.39 (CH₂Ph-C6), 70.77 (OCH₂Ph), 74.17 (NCH₂O), 91.86 (C-5), 127.41, 127.89, 128.09, 128.17, 128.70, 129.44, 135.05, 138.07 (aryl), 153.94 (C-6), 155.59 (C-2), 162.69 (C-4); m/z (ESI): 400.3, 402.2 (M+H)⁺.

4-amino-1-benzyloxymethyl-6-(3,5-dimethylbenzyl)-5-bromouracil (15b): white solid, yield 84%; mp 137–138°C; ¹H NMR (500 MHz, DMSO-d₆) δ 2.19 (s, 6H, 2CH₃), 4.27 (s, 2H, CH₂Ar), 4.60 (s, 2H, OCH₂Ph), 5.32 (s, 2H, NCH₂O), 6.69–7.43 (m, 8H, aryl), 7.89 (br, 2H, NH₂-C4); ¹³C NMR (125 MHz, DMSO-d₆) δ: 21.22 (CH₃Ar-C6), 41.70 (CH₂Ar-C6), 71.98 (OCH₂Ph), 74.20 (NCH₂O), 87.14 (C-5), 126.34, 127.5, 127.96, 128.18, 128.45, 128.87, 129.65, 133.43, 137.07, 140.09 (aryl), 153.47 (C-6), 156.14 (C-2), 163.23 (C-4); m/z (ESI): 428.4 (M+H)⁺.

Biological assays

Assay for Measuring the inhibitory Activity of Compounds against HIV-1 RT:

Oligo(dT) (TaKaRa Co., Japan) was immobilized via its 5'-terminal phosphate to Covalink-NH microtiter plates (NUNC Co., Denmark). The biotin-dUTP was incorporated by reverse transcriptase (Sigma). Briefly, a serial concentrations of inhibitor was added to the mixture, which contained 50 mmol/L Tris-HCl (pH 8.3), 3 mmol/L MgCl₂, 75 mmol/L KCl, 5 mmol/L DTT (DL-dithiothreitol), 0.13 mg/ml BSA (Albumin Bovine V), 10 µg/ml poly (A), 0.75 µM biotin-11-dUTP, and 1.5 µM dTTP. The reaction mixture was incubated at 37 °C for 1 h and washed with a buffer contained 50 mmol/L Tris-HCl (pH 7.5), 0.15 mol/L NaCl, 0.05 mmol/L MgCl₂, and 0.02% Tween-20. After 100 µl of 1% BSA was added to each well and incubated at room temperature for another 30 min, the plate was washed with the same buffer. Before further incubation at 37°C for 1 h, 50 µl of SA-ALP (Alkaline Phosphatase Streptavidin) solution (100 ng/ml) was added to per well, and washed again as above. Finally, 50 µl of PNPP (p-nitrophenyl phosphate, disodium) (1 mg/ml, pH 9.5) was added and incubated at 37 °C for 30 min. The reaction was stopped by addition of 0.5 M NaOH. The inhibitory activity of the compounds was detected and quantified using a colorimetric streptavidin-alkaline phosphatase reporter system.

Assay for Measuring the inhibitory Activity of Compounds on HIV-1_{SF33} and HIV-1_{A17} Replication in MT4:

MT4 cells, HIV-1_{SF33}, HIV-1_{IIIB}, and HIV-1_{A17} were obtained from the NIH AIDS Research and Reference Reagent Program (USA). The inhibitory activity of the compounds on infection by a laboratory-adapted HIV-1 strain SF33 and an NNRTI-resistant HIV-1 strain A17 was tested in MT4 cells. Briefly, MT4 cells (4×10⁴/well) were infected by addition of 200 TCID₅₀ of HIV-1, followed by incubation for 2 hrs at 37°C before addition of compounds at serial dilutions. After further incubation at 37°C for 7 days, p24 was measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Vironostika HIV-1 Microelisa system; BioMerieux; Marcy l'Etoile, France). The concentration of a compound for inhibiting 50% viral replication (EC₅₀) was determined by nonlinear regression using GraphPad Prism 5.01.

Assessment of in Vitro Cytotoxicity in MT-4 Cell: An XTT assay, as previously described,³³ was used to assess the cytotoxicity of target compounds to MT4 cells. Briefly, a compound at graded concentrations was added to MT4 cells (5×10⁴/well), followed by an incubation at 37°C for 3 days. Ten microliters of CCK-8 reagent was added to the cells.

After incubation at 37°C for 4 h to allow color development of the XTT formazan product, the absorbance of each well was then read at 450 nm in a Victor2 1420 Multilabel Counter (Wallace-PerkinElmer Life and Analytical Sciences Inc., Boston, MA). The percent of cytotoxicity and CC₅₀ (concentration causing 50% cytotoxicity) were calculated as previously described.³⁷

Molecular Modeling: The docking studies were conducted by using software GOLD3.0.1 and two protein crystal structures of wild-type RT/1 complex (PDB ID: 1RT2) and Y181C mutant RT/2 complex (PDB: 1JLA). Following the default setting of Chemscore in the software tool, top scored docked poses were visually inspected for each ligand in the DS 2.5 based on relevant molecules. The radius of the binding site sphere was defined by the original ligand as 8.9 Å, thus ensuring the docking method was reliable.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the NIH AIDS Research and Reference Reagent Program in the USA for providing MT4 cells, HIV-1_{SF33}, and HIV-1_{A17}. This study was supported by the National Science Foundation of China (20972011, 21042009, 21172014, 30872232, and 81172733) and grants from the Ministry of Science and Technology of China (2009ZX09301-010) and SKLID development grant (2011SKLID102) for financial support.

Abbreviations

CC ₅₀	concentration for 50% cytotoxicity
EC ₅₀	effective concentration for 50% inhibition
ELISA	enzyme-linked immunosorbent assay
HAART	highly active antiretroviral therapy
HIV-1	human immunodeficiency virus type 1
HEPT	(1-[2-hydroxyethoxy-methyl]-6-(phenylthio)thymine]
NNBP	non-nucleoside binding pocket
NNIBP	the non-nucleoside inhibitor binding pocket
NNRTI	non-nucleoside reverse transcriptase inhibitor
PDB	protein database
RT	reverse transcriptase
RTI	reverse transcriptase inhibitor
SI	selectivity index (ratio of CC ₅₀ /EC ₅₀)

References

1. Tronchet JM, Seman M. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: from the biology of reverse transcription to molecular design. *Curr Top Med Chem.* 2003; 3:1496–1511. [PubMed: 14529523]
2. Tarby CM. Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors. *Curr Top Med Chem.* 2004; 4:1045–1057. [PubMed: 15193138]

3. Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. *Curr HIV Res.* 2004; 2:323–332. [PubMed: 15544453]
4. De Clercq E. New developments in anti-HIV chemotherapy. *Biochim Biophys Acta.* 2002; 1587:258–275. [PubMed: 12084468]
5. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y, Stuart D, Stammers D. Highresolution structures of HIV-1 RT from four RT-inhibitor complexes. *Nat Struct Biol.* 1995; 2:293–302. [PubMed: 7540934]
6. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. *Nat Struct Biol.* 1995; 2:303–308. [PubMed: 7540935]
7. Smerdon SJ, Jager J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA, Steitz TA. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. *Proc Natl Acad Sci US A.* 1994; 91:3911–3915.
8. Jonckheere H, Anne J, De Clercq E. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. *Med Res Rev.* 2000; 20:129–154. [PubMed: 10723025]
9. Das K, Clark AD Jr, Lewi PJ, Heeres J, de Jonge MR, Koymans LMH, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, de Bethune MP, Boyer PL, Clark P, Hughes SH, Janssen PAJ, Arnold E. Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 Variants. *J Med Chem.* 2004; 47:2550–2560. [PubMed: 15115397]
10. Ding J, Das K, Tantillo C, Zhang W, Clark AJ, Jessen S, Lu X, Hsiou Y, Jacobo-Molina A, Andries K, Et A. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 Å resolution. *Structure.* 1995; 3:365–379. [PubMed: 7542140]
11. Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen PA, Hughes SH, Arnold E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. *Nat Struct Biol.* 1995; 2:407–415. [PubMed: 7545077]
12. Esnouf RM, Stuart DI, De Clercq E, Schwartz E, Balzarini J. Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives. *Biochem Biophys Res Commun.* 1997; 234:458–464. [PubMed: 9177293]
13. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. *Science.* 1995; 267:483–489. [PubMed: 7824947]
14. Ma L, Huang J, Xing H, Yuan L, Yu X, Sun J, Huang Y, Qu S, Feng Y, Liao L, Liu S, Shao Y. Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype B' strains from former blood donors in central Chinese provinces. *AIDS Res Hum Retroviruses.* 2010; 26:1007–1013. [PubMed: 20718629] Arnold E, Das K, Ding J, Yadav PN, Hsiou Y, Boyer PL, Hughes SH. Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. *Drug Des Discov.* 1996; 13:29–47. [PubMed: 8874042]
15. Ren J, Stammers DK. HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance. *Trends Pharmacol Sci.* 2005; 26:4–7. [PubMed: 15629197]
16. Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. *Prog Biophys Mol Biol.* 2005; 88:209–231. [PubMed: 15572156]
17. Ma L, Sun J, Xing H, Si X, Yuan L, Guo Y, Cheng H, Shao Y. Genotype and phenotype patterns of drug-resistant HIV-1 subtype B' (Thai B) isolated from patients failing antiretroviral therapy in China. *J Acquir Immune Defic Syndr.* 2007; 44:14–19. [PubMed: 17019361]
18. Baba M, De Clercq E, Tanaka H, Ubasawa M, Takashima H, Sekiya K, Nitta I, Umezaki K, Nakashima H, Mori S, Et A. Potent and selective inhibition of human immunodeficiency virus

- type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. *Proc Natl Acad Sci U S A*. 1991; 88:2356–2360. [PubMed: 1706522]
19. Campiani G, Ramunno A, Maga G, Nacci V, Fattorusso C, Catalanotti B, Morelli E, Novellino E. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. *Curr Pharm Des*. 2002; 8:615–657. [PubMed: 11945162]
20. Baba M, Tanaka H, Miyasaka T, Yuasa S, Ubasawa M, Walker RT, De Clercq E. Hept Derivatives: 6-Benzyl-1-ethoxymethyl-5-isopropyluracil (MKC-442). *Nucleosides Nucleotides*. 1995; 14:575–583.
21. Sankatsing SU, Weverling GJ, Peeters M, Van't KG, Gruzdev B, Rakhmanova A, Danner SA, Jurriaans S, Prins JM, Lange JM. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. *AIDS*. 2003; 17:2623–2627. [PubMed: 14685056]
22. Hopkins AL, Ren J, Esnouf RM, Willcox BE, Jones EY, Ross C, Miyasaka T, Walker RT, Tanaka H, Stammers DK, Stuart DI. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. *J Med Chem*. 1996; 39:1589–1600. [PubMed: 8648598]
23. Kireev DB, Chretien JR, Grierson DS, Monneret C. A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition. *J Med Chem*. 1997; 40:4257–4264. [PubMed: 9435895]
24. Esnouf RM, Ren J, Hopkins AL, Ross CK, Jones EY, Stammers DK, Stuart DI. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. *Proc Natl Acad Sci U S A*. 1997; 94:3984–3989. [PubMed: 9108091]
25. Mai A, Artico M, Sbardella G, Massa S, Novellino E, Greco G, Loi AG, Tramontano E, Marongiu ME, La Colla P. 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives. *J Med Chem*. 1999; 42:619–627. [PubMed: 10052969]
26. Hannick SM, Kishi Y. An improved procedure for the Blaise reaction: a short, practical route to the key intermediates of the saxitoxin synthesis. *J Org Chem*. 1983; 48:3833–3835.
27. Danel K, Larsen E, Pedersen EB. Easy Synthesis of 5,6-Disubstituted Acyclouridine Derivatives. *Synthesis*. 1995; 8:934–936.
28. Petersen L, Pedersen EB, Nielsen C. Three Routes for the Synthesis of 6-Benzyl-1-ethoxymethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbaldehyde. *Synthesis*. 2001; 4:559–564.
29. Wamberg M, Pedersen EB, Nielsen C. Synthesis of furoannelated analogues of Emivirine (MKC-442). *Arch Pharm (Weinheim)*. 2004; 337:148–151. [PubMed: 15038059]
30. Danel K, Larsen E, Pedersen EB, Vestergaard BF, Nielsen C. Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio)thymine. *J Med Chem*. 1996; 39:2427–2431. [PubMed: 8691437]
31. Muller CE, Thorand M, Qurishi R, Diekmann M, Jacobson KA, Padgett WL, Daly JW. Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. *J Med Chem*. 2002; 45:3440–3450. [PubMed: 12139454]
32. Elderfield R, Jesse W. Communications- Application of the Mannich Reaction with β , β -Dichlorodiethylamine to Derivatives of Uracil. *J Org Chem*. 1961; 26:3042–3043.
33. Sung WL. Synthesis of 4-(1,2,4-triazol-1-yl)-pyrimidin-2(1H)-one ribonucleotide and its application in synthesis of oligoribonucleotides. *J Org Chem*. 1982; 47:3623–3628.
34. Lavandera I, Fernandez SMF, Gotor V. Novel and efficient syntheses of 3',5'-diamino derivatives of 2',3',5'-trideoxycytidine and 2',3',5'-trideoxyadenosine. Protonation behavior of 3',5'-diaminonucleosides. *Tetrahedron*. 2003; 59:5449–5456.
35. Evelina C, Antonella C, Liguori A, Napoli A, Siciliano C, Sindona G. Simple and efficient routes for the preparation of isoxazolidinyl nucleosides containing cytosine and 5-methyl-cytosine as new potential anti-HIV drugs. *Tetrahedron*. 2001; 57:8551–8557.

36. Lu X, Chen Y, Guo Y, Liu Z, Shi Y, Xu Y, Wang X, Zhang Z, Liu J. The design and synthesis of N-1-alkylated-5-aminoarylalkylsubstituted-6-methyluracils as potential non-nucleoside HIV-1 RT inhibitors. *Bioorg Med Chem.* 2007; 15:7399–7407. [PubMed: 17870545]
37. Jiang S, Lu H, Liu S, Zhao Q, He Y, Debnath AK. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. *Antimicrob Agents Chemother.* 2004; 48:4349–4359. [PubMed: 15504864]

Figure 1.
Structure of **16** analogues and target compounds

Figure 2.
Superimposed stereoview of the docked **7a**, **7b**, **7c**, (blue) with **18** (green).

Figure 3.

Docking results of **7a** into the 1RT2 NNBP and **7b** into the NNBP of 1RT2 (a) and 1JLA Tyr181Cys (b). Hydrogen bonds are shown as a green dashed line, and halogen bond is shown as a green solid line.

Figure 4.
Docking results of **7b** into the 1RT2 NNBP

Scheme 1.

Reagents and conditions for chemical synthesis: (a) aryl acetonitrile, Zn/ THF, reflux (b) thiourea, EtONa, EtOH, reflux (c) 10% ClCH₂COOH, reflux (d) halogen, PbO₂, glacial acetic acid (e) alkyl halide, BSA, LiI, rt (f) NH(CH₃)₂ water-solution, 60 – 80°C (g) POCl₃, 1, 2, 4-*IH*-triazole, TEA, NH₃·H₂O, dioxane.

Table 1

Inhibitory activity of the target compounds against HIV-1 RT (**6a–15b**).

Compds	-C-4	R	R ¹	R ²	IC ₅₀ ^a	Compds	C-4	R	R ¹	R ²	IC ₅₀ ^a
6b	O	3,5-dimethyl	Me	I	0.110	6a	O	H	Me	I	0.114
7b	O	3,5-dimethyl	Ph	I	0.003	7a	O	H	Ph	I	0.010
8b	O	3,5-dimethyl	Me	Br	0.210	8a	O	H	Me	Br	1.825
9b	O	3,5-dimethyl	Ph	Br	0.043	9a	O	H	Ph	Br	1.521
10b	O	3,5-dimethyl	Me	N(CH ₃) ₂	0.039	10a	O	H	Me	N(CH ₃) ₂	0.162
11b	O	3,5-dimethyl	Ph	N(CH ₃) ₂	0.021	11a	O	H	Ph	N(CH ₃) ₂	0.012
12b	NH ₂	3,5-dimethyl	Me	I	ND ^c	12a	NH ₂	H	Me	I	ND ^c
13b	NH ₂	3,5-dimethyl	Ph	I	7.217	13a	NH ₂	H	Ph	I	ND ^c
14b	NH ₂	3,5-dimethyl	Me	Br	ND ^c	14a	NH ₂	H	Me	Br	ND ^c
15b	NH ₂	3,5-dimethyl	Ph	Br	16.338	15a	NH ₂	H	Ph	Br	ND ^c
NVP^b					4.120	6c	O	F	Me	I	11.85
17					0.150	7c	O	F	Ph	I	0.015
18					0.020						

^a Effective dose (μM) of the compounds required to inhibit HIV-1 RT activity by 50%.

^b Nevirapine (NVP), **17** and **18** were used as the reference compounds.

^c Not done

Table 2

The inhibitory activity of the compounds on HIV-1_{SF33} and HIV-1_{AI17} infection in MT4 cells^a

Compnd	MW	C ₅₀ (μM)	EC ₅₀ (μM) for inhibiting			SI ^b
			HIV-1 _{SF33}	HIV-1 _{AI17}	HIV-1 _{AI17}	
7a	448	74.84±1.67	0.045±0.014	>10	1,663	<7
11a	365	91.82±4.01	0.345±0.134	>10	264	<9
10a	303	166.34±8.75	0.614±0.423	>10	270	<16.6
9a	401	67.36±8.01	1.720±0.962	>10	39	<6.7
8a	339	155.27±6.05	2.071±1.321	>10	75	<15.5
7b	476	98.31±2.66	0.002±0.001	0.091±0.039	38,215	1,080
11b	393	55.81±2.19	0.014±0.009	2.198±0.445	5,201	25
9b	429	152.18±9.60	0.009±0.006	0.601±0.270	16,889	253
6b	414	141.52±1.86	0.006±0.005	0.637±0.145	23,667	222
6c	422	300.00±9.21	0.537±0.243	>10	559	<30
7c	484	121.25±4.27	0.006±0.002	2.543±0.404	20,208	48
NVP ^b	111	325.13±0.02	0.068±0.230	>10	4,781	<35
18	302	84.60±3.25	0.022±0.015	>10	3,845	<6.6

^a Each compound was tested in triplicate; the data were presented as the mean ± SD.

^b SI was calculated based on the CC₅₀ for MT4 cells and EC₅₀ for inhibiting infection of HIV-1_{SF33} and HIV-1_{AI17}, respectively. Nevirapine (NVP) and **18** were used as the reference compounds.